TP53 and neoplasm: However, we found that patients with deleterious mutations, but not those with missense mutations, were associated with worse OS and DFS compared to patients wild-type for TP53. This is in line with other tumor types, in which different types of TP53 mutations have been associated with different prognoses (Olivier et al., 2006; Ozcelik et al., 2007; Vegran et al., 2013; Lapke et al., 2016).